Dr Simon Crabb is an Associate Professor in Medical Oncology at the University of Southampton, UK. His research interests lie in the development of novel systemic treatment strategies for bladder and prostate cancers, cancer therapy resistance mechanisms, and epigenetic therapeutics. He was awarded his PhD in 2006 for research on the pre-clinical development of histone deacetylase inhibitors. This was followed by a post-doctoral training as a Clinical Research Fellow at the BC Cancer Agency in Vancouver and the Cancer Research UK Centre in Southampton. Dr Crabb holds several positions and titles. He is the Associate Clinical Director of the Southampton Clinical Trials Unit, Deputy Director of the Southampton Experimental Cancer Medicine Centre, Chair of the Genomics England Clinical Interpretation Partnership for bladder cancer, and a member of the NCRI Bladder and Renal Group, the NCRI Prostate Group, and the Experimental Medicine Expert Review Panel for Cancer Research UK. He is a lead for early phase cancer trials. He is an active contributor to the UK academic trials portfolio in urological malignancies, including as Chief Investigator for the SPIRE, AURORA, GUSTO, MANCAN2, and ProCAID trials.
EM-82389 - Date of preparation: November 2021